Field & Main Bank Sells 53 Shares of Stryker Co. (NYSE:SYK)

Field & Main Bank reduced its stake in Stryker Co. (NYSE:SYK) by 0.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,816 shares of the medical technology company’s stock after selling 53 shares during the period. Stryker accounts for 1.7% of Field & Main Bank’s holdings, making the stock its 13th biggest holding. Field & Main Bank’s holdings in Stryker were worth $4,137,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Farmers & Merchants Trust Co of Chambersburg PA boosted its holdings in Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. HBC Financial Services PLLC bought a new position in shares of Stryker in the 4th quarter worth $37,000. Bourgeon Capital Management LLC acquired a new stake in Stryker in the 4th quarter valued at $37,000. Operose Advisors LLC increased its stake in Stryker by 308.6% during the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock valued at $39,000 after purchasing an additional 108 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its holdings in Stryker by 97.1% during the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after buying an additional 67 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 1.0 %

Shares of NYSE SYK traded up $3.36 during trading hours on Monday, hitting $338.97. The company’s stock had a trading volume of 1,528,294 shares, compared to its average volume of 1,286,863. The business has a 50-day simple moving average of $348.68 and a 200-day simple moving average of $316.14. The stock has a market cap of $128.97 billion, a price-to-earnings ratio of 41.09, a P/E/G ratio of 2.70 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the company earned $3.00 earnings per share. The firm’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.80 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.94%. Stryker’s dividend payout ratio (DPR) is currently 38.79%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SYK. TD Cowen lifted their price objective on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Evercore ISI increased their price target on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and boosted their price target for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $340.67.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock valued at $72,845,768 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.